People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Pharmaceuticals, Biotechnology, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Attenua, Inc. | — | Pharmaceuticals | Series B | $15.2M | $517.0M | 2018 |
| Helicore Bioventures I, Inc. | — | Biotechnology | Series A | $15.0M | $99.0M | 2024 |
| Storelli Sports, Inc. | — | Retailing | Seed | $3.8M | $5.2M | 2014 |
Jing Liang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jing Liang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rishi Gupta | 1 | 12 |
| Kurt Von Emster | 1 | 6 |
| Martin Ott | 1 | 4 |
| Michael Kitt | 1 | 2 |
| Dina Chaya Moghrabi | 1 | 2 |
| Claudio Storelli | 1 | 2 |
| Todd Ruppert | 1 | 2 |
| Hugh Rienhoff | 1 | 1 |
| Matthew Weill | 1 | 1 |
| Hugh Young Rienhoff, Jr. | 1 | 1 |
| Patrick R Crutcher | 1 | 1 |
| Rishi Young Gupta | 1 | 1 |
| Brian Young Liu | 1 | 1 |
| Carl Young Rizzuto | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.